Research programme: urokinase plasminogen activator inhibitors - WilexAlternative Names: uPA inhibitors - Wilex; WX 508; WX 678; WX 77X series; WX-340
Latest Information Update: 22 Apr 2014
At a glance
- Originator Wilex
- Developer WILEX AG
- Class Small molecules
- Mechanism of Action Urokinase-type plasminogen activator inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours